A case of multiple myeloma with CD45 positive and CD45 negative neoplastic plasma cells

Öz

Multiple Myeloma (MM) is a type of cancer that affects the plasma cells proliferation in the bone marrow. When plasma cells that produce immunoglobulin (antibody), which are formed as a result of differentiation of B cells, turn into myeloma cells, they produce monoclonal protein (M-protein) instead of antibody. Myeloma cells are usually detected as CD45(-). In this article, we present a case of multiple myeloma carrying CD45(+) and CD45(-) cells together in a flow cytometric immunophenotyping study.

Anahtar Kelimeler

• CD45(+)
• CD45(-)
• multiple myeloma
• flow cytometry

CD45 pozitif ve CD45 negatif neoplastik plazma hücreleri saptanan multiple miyelom olgusu

Öz

Multiple Miyelom (MM) kemik iliğindeki plazma hücrelerinin üretimini etkileyen bir kanser türüdür. B hücrelerinin farklılaşması sonucu oluşan, immunglobulin (antikor) üreten plazma hücreleri miyelom hücresine dönüşünce, antikor yerine monoklonal protein (M-protein) üretirler. Miyeloma hücreleri genellikle CD45 ekspresyonu göstermezler. Bu makalede akım sitometrik immünfenotipleme çalışmasında CD45(+) ve CD45(-) hücreleri birlikte taşıyan bir multiple miyelom vakası sunulmaktadır.

Anahtar Kelimeler

• CD45(+)
• CD45(-)
• Multiple Miyelom
• akım sitometri

Kaynakça

1. 1. Ündar L. Plasma hücresi hastalıkları (Monoklonal Gammopatiler). İçinde: Çetin E, Yalçın A, eds. Hematoloji. 1. Baskı. Yenişehir, Ankara: MN Medikal & Nobel; 2008: 225-226.
2. 2. Schentrup D. Diagnosing multiple myeloma in primary care. Clinician Reviews. 2018;16-21.
3. 3. Ortolani C. Neoplastic diseases of mature B Cells. Flow cytometry of hematological malignancies. 1. Baskı. West Sussex: Wiley- Blackwell; 2011
4. 4. Rawstron AC. Immunophenotyping of plasma cells. current protocols in cytometry. https://currentprotocols.onlinelibrary.wiley.com/doi/epdf/10.1002/0471142956.cy0623s36. 2006’da basıldı. 2021’de erişildi
5. 5. Jeong TD, Park CJ, Shim H, et al. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. The Korean Journal of Hematology. 2012;47(4):260-6. doi:10.5045/kjh.2012.47.4.260
6. 6. Gonsalves WI, Timm MM, Rajkumar SV, et al. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research. 2016;44:32-39. doi.org/10.1016/j.leukres.2016.03.003
7. 7. Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations . Leukemia. 2005;19:1466–1470. doi:10.1038/sj.leu.2403823
8. 8. Rawstron AC, Orfao A, Beksac M, et al. On behalf of the European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431-438. doi: 10.3324/haematol.11080